Seer, Inc.
SEER Healthcare Biotechnology
Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow SEER
Seer, Inc. (SEER) EV/Sales
As of 16 October 2026, Seer, Inc. (SEER) trades at a EV/Sales of −2.9×. Over the past ten years it has ranged from −14.1× (November 2023) to 5,319× (April 2021); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −4.9× | — |
| FY2024 | −6.5× | — |
| FY2023 | −11.5× | — |
| FY2022 | −3.6× | — |
| FY2021 | 149× | (89.23%) |
| FY2020 | 1,386× | 5.94% |
| FY2019 | 1,309× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −4.3× | — |
| Mar 2026 | −4.8× | — |
| Dec 2025 | −4.9× | — |
| Sep 2025 | −4.7× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. | −2.9× |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −2.3× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| ENGN enGene Therapeutics Inc compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| GNLX Genelux Corporation compare | 8.8× |
| ARMP Armata Pharmaceuticals, Inc. compare | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)